fracasso, giulio
fracasso, giulio
Dipartimento di Scienze Biomediche - DSB
Point mutations of the mitochondrial chaperone TRAP1 affect its functions and pro-neoplastic activity
2025 Laquatra, Claudio; Magro, Alessia; Guarra, Federica; Lambrughi, Matteo; Ferrone, Lavinia; Fracasso, Giulio; Bacchin, Melissa; La Spina, Martina; Moroni, Elisabetta; Papaleo, Elena; Colombo, Giorgio; Rasola, Andrea
Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer
2024 Bolzati, Cristina; Gobbi, Carolina; Ferro-Flores, Guillermina; Turato, Sofia; Ocampo-Garcia, Blanca; Carpanese, Debora; Marzano, Cristina; Spolaore, Barbara; Fracasso, Giulio; Rosato, Antonio; Meléndez-Alafort, Laura
D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer
2023 Sarkis, M.; Minassian, G.; Mitri, N.; Rahme, K.; Fracasso, G.; El Hage, R.; Ghanem, E.
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children
2023 Dallatana, Alessia; Cremonesi, Linda; Trombetta, Maddalena; Fracasso, Giulio; Nocini, Riccardo; Giacomello, Luca; Innamorati, Giulio
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy
2023 Canè, Stefania; Maria Barouni, Roza; Fabbi, Marina; Cuozzo, John; Fracasso, Giulio; Adamo, Annalisa; Ugel, Stefano; Trovato, Rosalinda; De Sanctis, Francesco; Giacca, Mauro; Lawlor, Rita; Scarpa, Aldo; Rusev, Borislav; Lionetto, Gabriella; Paiella, Salvatore; Salvia, Roberto; Bassi, Claudio; Mandruzzato, Susanna; Ferrini, Silvano; Bronte, Vincenzo
Preclinical dosimetric studies of 177Lu-scFvD2B, 177Lu-PSMA-617 and 177Lu-iPSMA
2023 Melendez-Alafort, Laura; FERRO-FLORES, Guillermina; Eli Ocampo-García, Blanca; Santos-Cuevas, Clara; Turato, Sofia; Fracasso, Giulio; Bolzati, Cristina; Rosato, Antonio; DE NARDO, Laura
Upgrading gold to green nanoparticles: applications in prostate cancer
2023 Mitri, N.; Rahme, K.; Fracasso, G.; Ghanem, E.
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers
2023 Fracasso, G.; Falvo, E.; Tisci, G.; Sala, G.; Colotti, G.; Cingarlini, S.; Tito, C.; Bibbo, S.; Frusteri, C.; Tremante, E.; Giordani, E.; Giacomini, P.; Ceci, P.
Comparison of preclinical dosimetric studies of 177Lu-scFvD2B, 177Lu-PSMA-617 and 177Lu-iPSMA.
2022 Meléndez-Alafort, Laura; Ferro-Flores, Guillermina; Ocampo-Garcia, Blanca; Santos-Cuevas, Clara; Carpanese, Debora; Fracasso, Giulio; Bolzati, Cristina; Rosato, Antonio; DE NARDO, Laura
Human blood biocompatibility and immunogenicity of scFvD2B PEGylated gold nanoparticles
2022 Mitri, N.; Rahme, K.; Fracasso, G.; Ghanem, E.
D2B antibody and its scFvD2B fragment in nanomedicine: Promising tools in the theranostics of prostate cancer
2021 Mitri, N.; Rahme, K.; Fracasso, G.; Ghanem, E.
Design and evaluation of 223Ra-labeled and Anti-PSMA targeted NaA nanozeolites for prostate cancer therapy—part ii. Toxicity, pharmacokinetics and biodistribution
2021 Lankoff, A.; Czerwinska, M.; Walczak, R.; Karczmarczyk, U.; Tomczyk, K.; Brzoska, K.; Fracasso, G.; Garnuszek, P.; Mikolajczak, R.; Kruszewski, M.
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors
2021 Falvo, E.; Damiani, V.; Conti, G.; Boschi, F.; Messana, K.; Giacomini, P.; Milella, M.; De Laurenzi, V.; Morea, V.; Sala, G.; Fracasso, G.; Ceci, P.
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model
2021 Conti, G.; Pitea, M.; Ossanna, R.; Opri, R.; Tisci, G.; Falvo, E.; Innamorati, G.; Ghanem, E.; Sbarbati, A.; Ceci, P.; Fracasso, G.
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents
2021 Amendola, Vincenzo; Guadagnini, Andrea; Agnoli, Stefano; Badocco, Denis; Pastore, Paolo; Fracasso, Giulio; Gerosa, Marco; Vurro, Federica; Busato, Alice; Marzola, Pasquina
Preclinical dosimetric studies of 177Lu-scFvD2B and comparison with 177Lu-PSMA-617 and 177Lu-iPSMA endoradiotherapeutic agents
2021 Melendez-Alafort, L.; Ferro-Flores, G.; Santos-Cuevas, C.; Ocampo-Garcia, B.; Turato, S.; Fracasso, G.; Bolzati, C.; Rosato, A.; De Nardo, L.
PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB "Super-Stimulation"
2021 Zuccolotto, Gaia; Penna, Alessandro; Fracasso, Giulio; Carpanese, Debora; Montagner, Isabella Monia; Dalla Santa, Silvia; Rosato, Antonio
Simple and rapid non-enzymatic procedure allows the isolation of structurally preserved connective tissue micro-fragments enriched with svf
2021 Busato, A.; De Francesco, F.; Biswas, R.; Mannucci, S.; Conti, G.; Fracasso, G.; Conti, A.; Riccio, V.; Riccio, M.; Sbarbati, A.
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer
2020 Montagner, I. M.; Penna, A.; Fracasso, G.; Carpanese, D.; Pieta, A. D.; Barbieri, V.; Zuccolotto, G.; Rosato, A.
Conjugation and characterization of a new prostate cancer theranostic radiopharmaceutical
2020 Meléndez-Alafort, L; Carpanese, D; Ferro-Flores, G; Ocampo-Garcia, B; Santos-Cuevas, C; Fracasso, G; De Nardo, L; Bolzati, C; Rosato, A